Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Strategies for developing effective radioimmunotherapy for solid tumors.

G L DeNardo1, R T O'Donnell, L A Kroger

  • 1Department of Internal Medicine, University of California Davis Medical Center, Sacramento 95816, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 29, 1999
PubMed
Summary

Radioimmunotherapy (RIT) shows promise for solid tumors when combined with synergistic agents like taxanes. Optimizing radiopharmaceuticals and understanding apoptosis pathways are key to improving RIT efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac sympathetic denervation without Lewy bodies in a case of multiple system atrophy.

Parkinsonism & related disorders·2014
Same author

Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases.

Endocrine regulations·2011
Same author

Catechols in post-mortem brain of patients with Parkinson disease.

European journal of neurology·2010
Same author

Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation.

Neurology·2007
Same author

Cardiovascular aspects of Parkinson disease.

Journal of neural transmission. Supplementum·2006
Same author

Glucagon does not affect catecholamine release in primary cultures of bovine adrenal chromaffin cells.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2005

Area of Science:

  • Oncology
  • Radiopharmaceutical Therapy
  • Molecular Biology

Background:

  • Single-agent radioimmunotherapy (RIT) is effective for hematological malignancies but less so for solid tumors due to radioresistance.
  • Bone marrow transplantation-supported RIT has yielded marginal results for solid tumors.

Purpose of the Study:

  • To provide an overview of promising RIT strategies for solid tumors.
  • To highlight the need for combination therapies and radiopharmaceutical optimization.

Main Methods:

  • Review of preclinical and clinical data on RIT strategies for solid tumors.
  • Discussion of radiopharmaceutical optimization, including metallic radionuclides and biodegradable peptide linkers.
  • Exploration of synergistic therapies targeting apoptosis pathways (p53, Bcl-2) and cell cycle arrest (G2-M phase).

Related Experiment Videos

Main Results:

  • Metallic radionuclides can increase tumor radiation dose but not always the therapeutic index.
  • Biodegradable peptide linkers enhance the therapeutic index in RIT.
  • Taxanes show potential as synergistic agents by inducing apoptosis and cell cycle arrest.

Conclusions:

  • Combination therapy is essential for effective RIT in solid tumors.
  • Optimizing radiopharmaceuticals and identifying synergistic agents like taxanes are crucial.
  • Strategic sequencing and timing of combined modality RIT are critical for achieving synergy.